A Study of HS-20110 in Participants With Advanced Solid Tumors (NCT06892379)

🧪 Interventions in This Study

• HS-20110 (Phase Ia：Dose escalation ) (DRUG)
• HS-20110 (Phase Ib:Dose expansion ) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (8 Sites)

• BRCR Medical Center INC — Tamarac, Florida
• Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
• Carolina BioOncology Institute — Huntersville, North Carolina
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• NEXT Dallas — Irving, Texas
• NEXT Oncology — San Antonio, Texas
• NEXT Virginia — Fairfax, Virginia
• SUN YAT-SEN University Cancer Center — Guangzhou, Guangdong

📞 Contact the Study Coordinator

Phone: (511) 191-5273

Email: wanghy10@hspharm.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.